TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)

Grant

Date/time Interval

  • October 19, 2016 - October 18, 2021
  • Total Award Amount

  • 48812.00
  • Direct Costs

  • 38740.00
  • Sponsor Award Id

  • Contributor

  • Stringer-Reasor M.D., Erica   Investigator